BR9711734A - Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila - Google Patents

Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila

Info

Publication number
BR9711734A
BR9711734A BR9711734A BR9711734A BR9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A BR 9711734 A BR9711734 A BR 9711734A
Authority
BR
Brazil
Prior art keywords
alpha
monochlorochloride
metäxiimino
azabicyclo
alfa
Prior art date
Application number
BR9711734A
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Plc
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beckman Corp filed Critical Smithkline Beecham Plc
Publication of BR9711734A publication Critical patent/BR9711734A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9711734A 1996-09-12 1997-09-08 Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila BR9711734A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (1)

Publication Number Publication Date
BR9711734A true BR9711734A (pt) 1999-08-24

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711734A BR9711734A (pt) 1996-09-12 1997-09-08 Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila

Country Status (22)

Country Link
EP (1) EP0929301A2 (https=)
JP (1) JP2001500150A (https=)
KR (1) KR20000036039A (https=)
CN (2) CN1235544A (https=)
AR (1) AR008176A1 (https=)
AU (1) AU724086B2 (https=)
BR (1) BR9711734A (https=)
CA (1) CA2265661A1 (https=)
CO (1) CO5031291A1 (https=)
CZ (1) CZ83299A3 (https=)
GB (1) GB9619074D0 (https=)
HU (1) HUP9904401A3 (https=)
ID (1) ID19589A (https=)
IL (1) IL128781A0 (https=)
MA (1) MA24359A1 (https=)
NO (1) NO991194D0 (https=)
NZ (1) NZ334268A (https=)
PE (1) PE2499A1 (https=)
PL (1) PL332074A1 (https=)
TR (1) TR199900505T2 (https=)
WO (1) WO1998010762A2 (https=)
ZA (1) ZA978133B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
JP2002506031A (ja) 1998-03-11 2002-02-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 組成物
DE19918325A1 (de) * 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
FR2796840B1 (fr) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6733781B2 (en) * 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
JP4808612B2 (ja) 2003-04-25 2011-11-02 田辺三菱製薬株式会社 アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
ATE339192T1 (de) * 2003-05-14 2006-10-15 Eurand Pharmaceuticals Ltd Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
CN101022788B (zh) 2004-08-13 2010-11-10 贝林格尔·英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途
UA93608C2 (ru) 2004-08-13 2011-02-25 Берингер Ингельхайм Интернациональ Гмбх композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2020214879A1 (en) * 2019-04-19 2020-10-22 Steven Hoffman Sustained release formulations
WO2026013570A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013566A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013573A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026013563A1 (en) 2024-07-09 2026-01-15 Syremis Therapeutics Ltd. New salt forms of sabcomeline
WO2026018154A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with non-cns penetrant muscarinic antagonists
WO2026018155A1 (en) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.

Also Published As

Publication number Publication date
AR008176A1 (es) 1999-12-09
NO991194L (no) 1999-03-11
WO1998010762A2 (en) 1998-03-19
AU724086B2 (en) 2000-09-14
EP0929301A2 (en) 1999-07-21
JP2001500150A (ja) 2001-01-09
CO5031291A1 (es) 2001-04-27
CN1446535A (zh) 2003-10-08
NZ334268A (en) 2000-10-27
PE2499A1 (es) 1999-03-24
ID19589A (id) 1998-07-23
WO1998010762A3 (en) 1998-06-04
PL332074A1 (en) 1999-08-30
AU4128897A (en) 1998-04-02
NO991194D0 (no) 1999-03-11
ZA978133B (en) 1999-04-12
CN1235544A (zh) 1999-11-17
CZ83299A3 (cs) 1999-08-11
GB9619074D0 (en) 1996-10-23
HUP9904401A3 (en) 2001-03-28
HUP9904401A2 (hu) 2000-06-28
IL128781A0 (en) 2000-01-31
MA24359A1 (fr) 1998-07-01
TR199900505T2 (https=) 1999-06-21
CA2265661A1 (en) 1998-03-19
KR20000036039A (ko) 2000-06-26

Similar Documents

Publication Publication Date Title
BR9711734A (pt) Forma de dosagem de libera-Æo controlada de monochidrocloreto de ¬r-(z)¾-alfa-(metÄxiimino)-alfa-(1-azabiciclo¬2.2.2¾oct-3-il)acetonitrila
EE03903B1 (et) Omeprasooli ravimvorm
IS5722A (is) Pýróló [2,3-dl]pírimídín efnasambönd
PT1087970E (pt) Compostos pirrolo¬2,3-d|pirimidina
FI945621L (fi) Säädetysti vapauttava valmiste
BR9706897B1 (pt) forma de dosagem farmacêutica.
DE69816852D1 (de) Zyklonabscheider
DE69804995D1 (de) Zyklonabscheider
EE04293B1 (et) Stabiilsed lüofiliseeritud ravimvormid
GB9823101D0 (en) Pharmaceutically active compounds
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
DK0891978T3 (da) 5H-Thiazol(3,2-a)pyrimidinderivativer
DK0839039T3 (da) Paroxetinpræparater med styret frigivelse
ATE321784T1 (de) Pthrp analogen
NO20002451D0 (no) Kondenserte pyrazinforbindelser
IS4848A (is) Lyfjafræðilega gagnleg efnasambönd
GB9823102D0 (en) Pharmaceutically active compounds
ZA977807B (en) New pharmaceutically active compounds.
EE200000022A (et) Uus ravimvorm
GB0110612D0 (en) Controlled-release garlic formulations
DE59804098D1 (de) Verdampferanordnung
PT964867E (pt) Antagonistas da taquicinima
PL338781A1 (en) Dosage form
NO995035D0 (no) 5,6,7-trisubstituerte-4-aminopyrido[2,3-D]pyrimidinforbindelser
ID16434A (id) Senyawa-senyawa 1,4-dihidropiridin

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.